The aim of this study is to analyse molecular alterations predictive for anti-EGFR therapies response, such as EGFR gene status, K-Ras and BRAF mutations, and PTEN protein expression, in primary tumour and synchronous or metachronous metastasis. The gene discussed is EGFR; the disease is neoplasm.